The Prevalence and Management of Saliva Problems in Motor Neuron Disease: A 4-Year Analysis of the Scottish Motor Neuron Disease Register.
Hypersalivation
Motor neuron disease
Saliva problem
Journal
Neuro-degenerative diseases
ISSN: 1660-2862
Titre abrégé: Neurodegener Dis
Pays: Switzerland
ID NLM: 101189034
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
09
2020
accepted:
28
12
2020
pubmed:
27
4
2021
medline:
29
10
2021
entrez:
26
4
2021
Statut:
ppublish
Résumé
Saliva problems are common and distressing for people with motor neuron disease (pwMND). Despite clinical guidelines for assessment and treatment, management of saliva problems has received little research attention. We aimed to investigate the prevalence of saliva problems in pwMND, their association with clinical factors, and their management practice using a highly curated population-based register for motor neuron disease (MND) with 99% case ascertainment. We conducted an analysis of pwMND diagnosed between January 2015 and October 2019 using the Scottish MND Register (CARE-MND [Clinical, Audit, Research, and Evaluation of MND]). The association between clinical factors and saliva problems was investigated using univariate and multivariable logistic regression; results are reported as odds ratio (OR) and 95% confidence intervals. A survey of health-care professionals involved in the care of pwMND was performed to contextualize the findings. 939 pwMND were included. Prevalence of saliva problems was 31.3% (294). Bulbar onset (OR 9.46 [4.7, 19.2]; p < 0.001) but not age, sex, time to diagnosis, or MND subtype were independently associated with the presence of saliva problems in multivariable regression, and 52.7% (155) of those with saliva problems received pharmacological management. The most commonly used medications were hyoscine, amitriptyline, carbocisteine, glycopyrrolate, and atropine. Evidence base (8, 72.7%) and local guidelines (10, 90.9%) were cited as the most important factors influencing treatment decision by survey respondents (n = 11). Saliva problems are common and associated with bulbar onset MND. A substantial proportion of pwMND with saliva problems did not receive recommended treatments. Future research is required to determine the relative efficacy of individual pharmacological treatments.
Identifiants
pubmed: 33902047
pii: 000514615
doi: 10.1159/000514615
pmc: PMC7610776
mid: EMS123326
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
147-152Subventions
Organisme : Motor Neurone Disease Association
ID : MEHTA/JUL17/948-795
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R001162/1
Pays : United Kingdom
Informations de copyright
© 2021 S. Karger AG, Basel.
Références
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):521-7
pubmed: 23647474
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):21-28
pubmed: 29037065
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):589-95
pubmed: 24411632
J Neurol Sci. 1999 Oct 31;169(1-2):13-21
pubmed: 10540002
Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):198-205
pubmed: 26824413
Neurology. 2001 Aug 14;57(3):500-4
pubmed: 11502920
Ther Adv Neurol Disord. 2019 Nov 28;12:1756286419888601
pubmed: 31819763
J Neurol Sci. 2011 Sep 15;308(1-2):155-7
pubmed: 21726879
Muscle Nerve. 2012 Mar;45(3):311-8
pubmed: 22334165
Degener Neurol Neuromuscul Dis. 2019 Mar 20;9:19-26
pubmed: 31118868
J Neurol. 2019 Apr;266(4):817-825
pubmed: 30805795
Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):302-7
pubmed: 23134507
Acta Neurol Scand. 2016 Sep;134(3):224-31
pubmed: 26803950